REPLIGEN CORP (RGEN) Stock Fundamental Analysis

NASDAQ:RGEN • US7599161095

134.67 USD
-0.73 (-0.54%)
At close: Feb 24, 2026
134.67 USD
0 (0%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. While showing a medium growth rate, RGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year RGEN was profitable.
  • In the past year RGEN had a positive cash flow from operations.
  • Of the past 5 years RGEN 4 years were profitable.
  • Each year in the past 5 years RGEN had a positive operating cash flow.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • RGEN has a better Return On Assets (0.06%) than 67.24% of its industry peers.
  • The Return On Equity of RGEN (0.08%) is better than 68.97% of its industry peers.
  • RGEN's Return On Invested Capital of 1.05% is fine compared to the rest of the industry. RGEN outperforms 60.34% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 11.97%.
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROIC 1.05%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8

1.3 Margins

  • RGEN's Profit Margin of 0.25% is fine compared to the rest of the industry. RGEN outperforms 67.24% of its industry peers.
  • RGEN's Operating Margin of 6.58% is fine compared to the rest of the industry. RGEN outperforms 60.34% of its industry peers.
  • In the last couple of years the Operating Margin of RGEN has declined.
  • The Gross Margin of RGEN (51.59%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of RGEN has declined.
Industry RankSector Rank
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
  • RGEN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RGEN has been increased compared to 5 years ago.
  • The debt/assets ratio for RGEN has been reduced compared to a year ago.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 6.34 indicates that RGEN is not in any danger for bankruptcy at the moment.
  • RGEN has a better Altman-Z score (6.34) than 89.66% of its industry peers.
  • The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RGEN (5.05) is better than 67.24% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
  • RGEN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: RGEN outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Altman-Z 6.34
ROIC/WACC0.1
WACC10.43%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

  • RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
  • RGEN has a better Current ratio (8.36) than 91.38% of its industry peers.
  • A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 7.14, RGEN belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.14
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
  • RGEN shows a decrease in Revenue. In the last year, the revenue decreased by -8.54%.
  • RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%

3.2 Future

  • RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.04% yearly.
  • RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.19% yearly.
EPS Next Y14.82%
EPS Next 2Y19.82%
EPS Next 3Y22.25%
EPS Next 5Y24.04%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.34%
Revenue Next 5Y16.19%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 81.13, which means the current valuation is very expensive for RGEN.
  • RGEN's Price/Earnings is on the same level as the industry average.
  • RGEN is valuated expensively when we compare the Price/Earnings ratio to 26.98, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 63.38, the valuation of RGEN can be described as expensive.
  • RGEN's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. RGEN is valued rather expensively when compared to this.
Industry RankSector Rank
PE 81.13
Fwd PE 63.38
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
Industry RankSector Rank
P/FCF 71.19
EV/EBITDA 66.78
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.25% in the coming years.
PEG (NY)5.47
PEG (5Y)11.42
EPS Next 2Y19.82%
EPS Next 3Y22.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REPLIGEN CORP

NASDAQ:RGEN (2/24/2026, 8:00:01 PM)

After market: 134.67 0 (0%)

134.67

-0.73 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-28
Earnings (Next)02-24
Inst Owners110.6%
Inst Owner Change-0.01%
Ins Owners0.45%
Ins Owner Change-2.86%
Market Cap7.58B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target194.44 (44.38%)
Short Float %7.73%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.29%
PT rev (3m)1.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE 81.13
Fwd PE 63.38
P/S 10.71
P/FCF 71.19
P/OCF 57.92
P/B 3.64
P/tB 13.19
EV/EBITDA 66.78
EPS(TTM)1.66
EY1.23%
EPS(NY)2.12
Fwd EY1.58%
FCF(TTM)1.89
FCFY1.4%
OCF(TTM)2.33
OCFY1.73%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)5.47
PEG (5Y)11.42
Graham Number37.18
Profitability
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROCE 1.67%
ROIC 1.05%
ROICexc 1.43%
ROICexgc 5.46%
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
FCFM 15.04%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Debt/EBITDA 4.85
Cap/Depr 37.9%
Cap/Sales 3.45%
Interest Coverage 250
Cash Conversion 117.95%
Profit Quality 6126.58%
Current Ratio 8.36
Quick Ratio 7.14
Altman-Z 6.34
F-Score6
WACC10.43%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.82%
EPS Next 2Y19.82%
EPS Next 3Y22.25%
EPS Next 5Y24.04%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.34%
Revenue Next 5Y16.19%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.02%
EBIT Next 5Y34.6%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%

REPLIGEN CORP / RGEN FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


What is the profitability of RGEN stock?

REPLIGEN CORP (RGEN) has a profitability rating of 5 / 10.


What is the financial health of REPLIGEN CORP (RGEN) stock?

The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.82% in the next year.